AC Immune is a clinical stage biopharmaceutical company focused on neurodegenerative diseases with six product candidates in clinical trials. Co.'s products include: Semorinemab, which is proposed to slow the prion-like propagation of Tau pathology; ACI-35, which targets pathological Tau and is intended as a disease-modifying treatment for Alzheimer's disease (AD) and other Tauopathies; ACI-24, in which it owns the global rights to ACI-24 and it continues to develop ACI-24 in-house as a therapeutic candidate; ACI-24 for AD; and diagnostic candidates, in which it continues to develop its complementary diagnostic product candidates for Tau, alpha-synuclein and Tar DNA-binding Protein. The ACIU stock yearly return is shown above.
The yearly return on the ACIU stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ACIU annual return calculation with any dividends reinvested as applicable (on ex-dates).
|